# RxVantage

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rxvantage

- Industry: Healthcare IT
- Headquarters: El Segundo, US
- Website: www.rxvantage.com
- Total disclosed funding: $2.5M
- Latest round: Series B (Jan 1, 2020)
- Investors on record: 3

## About

RxVantage, Inc. is a technology company that specializes in connecting healthcare providers with life science companies through an intuitive platform designed to streamline educational exchanges and enhance communication.Founded in 2008, RxVantage, Inc. is headquartered in El Segundo, US. The company provides a platform that facilitates connections between healthcare providers and life science companies. The founders, Greg Gilman, James Dwyer, and Jeremy Gilman, have previously established successful ventures. In its funding journey, RxVantage secured USD 2.00 mn in a SERIES A funding round led by Javelin Venture Partners, bringing the total amount raised to USD 2.00 mn. The company has completed 6 deals to date.RxVantage offers a robust platform designed to facilitate connections between healthcare providers and life science companies, streamlining the educational exchange process. Their core product is an easy-to-use application that enables medical practices to access educational resources, engage with life science representatives, and manage scheduling for meetings efficiently. This solution addresses key challenges faced by healthcare providers, including the need for timely updates on medications, treatment protocols, and patient assistance programs. RxVantage serves a diverse clientele, including over 16,000 medical practices and 100,000 life science experts, primarily within the United States and select international markets. The platform's emphasis on transparency and control allows practices to dictate rep access to clinical areas while ensuring that interactions are relevant and focused on improving patient care.RxVantage generates revenue through a subscription model that connects medical practices with life science representatives and educational resources. Clients pay for access to the platform's features, which include meeting scheduling, instant communication with representatives, and access to a resource library for patient assistance programs. Revenue is derived primarily from healthcare practices subscribing to the service on an annual or monthly basis, establishing a steady income stream. The business model also includes partnerships with life science companies, enhancing the value proposition for both providers and representatives. By offering a comprehensive and user-friendly solution, RxVantage positions itself as an essential tool for enhancing operational efficiency in medical practices, ensuring that providers can focus on delivering quality patient care while benefiting from timely and relevant information.RxVantage plans to leverage its recent funding to enhance its platform with new product features designed to improve user engagement and data analytics capabilities. The company aims to expand into new markets, particularly targeting Europe and Asia by 2025. Recent funding will be utilized to support product development and market entry strategies. Additionally, Wavemaker Partners has exited their stake in RxVantage, Inc., although financial terms were not disclosed.

## Funding rounds

- Series B, Jan 1, 2020 — dRx Capital
- Series A, Dec 31, 2011, $2M — Javelin Venture Partners
- Seed, Jun 1, 2009, $0.5M — Slater Technology Fund

## Investors

- Slater Technology Fund (https://capitalatlas.ai/funds/slater-technology-fund) — Seed
- Javelin Venture Partners (https://capitalatlas.ai/funds/javelin-venture-partners) — Series A
- dRx Capital (https://capitalatlas.ai/funds/drx-capital) — Series B